These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 3102281)
1. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Percival RC; Urwin GH; Harris S; Yates AJ; Williams JL; Beneton M; Kanis JA Eur J Surg Oncol; 1987 Feb; 13(1):41-9. PubMed ID: 3102281 [TBL] [Abstract][Full Text] [Related]
2. Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. Smith R; Russell RG; Bishop MC; Woods CG; Bishop M Q J Med; 1973 Apr; 42(166):235-56. PubMed ID: 4206518 [No Abstract] [Full Text] [Related]
3. Markers of bone turnover in prostate cancer. Garnero P Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970 [TBL] [Abstract][Full Text] [Related]
4. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. McCloskey EV; Yates AJ; Beneton MN; Galloway J; Harris S; Kanis JA Bone; 1987; 8 Suppl 1():S35-41. PubMed ID: 2825741 [TBL] [Abstract][Full Text] [Related]
5. [Treatment of Paget's disease of bone: diphosphonates or calcitonin?]. Davoine GA; Jung A; Courvoisier B Schweiz Med Wochenschr; 1981 Apr; 111(15):518-24. PubMed ID: 6785879 [TBL] [Abstract][Full Text] [Related]
6. [Effects of the combined calcitonin and sodium etidronate therapy in Paget's disease of bone]. Nuti R; Turchetti V; Righi G; Vattimo A Minerva Med; 1982 Mar; 73(9):467-72. PubMed ID: 6801555 [TBL] [Abstract][Full Text] [Related]
7. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma. Papatheofanis FJ J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144 [TBL] [Abstract][Full Text] [Related]
8. Metabolic consequences of bone turnover in Paget's disease of bone. Krane SM; Simon LS Clin Orthop Relat Res; 1987 Apr; (217):26-36. PubMed ID: 3549093 [TBL] [Abstract][Full Text] [Related]
9. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374 [TBL] [Abstract][Full Text] [Related]
10. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759 [TBL] [Abstract][Full Text] [Related]
11. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813 [TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of Paget's disease of bone with ethane-1 hydroxy-1, 1 diphosphonate at low dosage (author's transl)]. Alexandre C; Chapuy MC; Bressot C; Vignon E; Arlot M; Mathieu L; Edouard C; Johnston CC; Meunier PJ Nouv Presse Med; 1980 Nov; 9(45):3429-33. PubMed ID: 6777752 [TBL] [Abstract][Full Text] [Related]
14. Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. Charles P; Poser JW; Mosekilde L; Jensen FT J Clin Invest; 1985 Dec; 76(6):2254-8. PubMed ID: 3878367 [TBL] [Abstract][Full Text] [Related]
15. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma. Berruti A; Tucci M; Dogliotti L; Scarpa RM; Angeli A Cancer; 2002 Sep; 95(5):1182-3; author reply 1183-4. PubMed ID: 12209706 [No Abstract] [Full Text] [Related]
16. [Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results]. Bouvier M; Colson F; Tebib J; Mathieu M; Vianey-Liaud C Pathol Biol (Paris); 1986 Apr; 34(4):235-9. PubMed ID: 3528996 [TBL] [Abstract][Full Text] [Related]
17. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. Yavropoulou MP; van Lierop AH; Hamdy NA; Rizzoli R; Papapoulos SE Bone; 2012 Jul; 51(1):153-7. PubMed ID: 22579776 [TBL] [Abstract][Full Text] [Related]
18. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of Paget's disease with low dose sodium etidronate (5mg/kg/day). Occurrence of reversible transient suspected leukopenia]. Reginster JY; Gritten C; Diverse P; Hauwaert PC; Crielaard JM; Halleux R; Franchimont P Rev Rhum Mal Osteoartic; 1985 Mar; 52(3):145-50. PubMed ID: 3923603 [TBL] [Abstract][Full Text] [Related]
20. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]